Welcome to our dedicated page for Oriental Rise SEC filings (Ticker: ORIS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oriental Rise Holdings Limited (NASDAQ: ORIS) files reports and updates with the U.S. Securities and Exchange Commission as a foreign private issuer. These SEC filings provide detailed information on the company’s vertically integrated tea operations in mainland China, its financial performance, capital structure, and corporate actions.
Among the key documents available are Form 6-K current reports. In its interim 2025 results furnished on Form 6-K, Oriental Rise presents revenue by product category, including primarily-processed white tea, primarily-processed black tea, and refined tea, and explains how changes in selling prices, sales volumes, and market conditions have affected revenue, gross profit, and margins. The filing also breaks down cost of sales into plantation and processing costs, and describes the components of selling and distribution costs and administrative expenses, offering insight into the company’s cost structure.
Other 6-K filings cover capital markets transactions, such as the pricing of public offerings of units consisting of ordinary shares and warrants, the terms of those warrants, and intended uses of proceeds for sales network expansion, production and capacity expansion, and working capital. Filings also document corporate governance and capital structure changes, including shareholder approvals for increasing authorized share capital, designating Founder Preferred Shares with enhanced voting rights, issuing those shares to a company owned by the founder and largest shareholder, and authorizing a potential share consolidation within a defined ratio range.
Regulatory compliance and listing status are addressed in filings that describe Nasdaq notifications regarding the minimum bid price requirement and the company’s potential options, including a reverse stock split, to regain compliance. Board and management changes, such as director resignations and appointments, are also reported through Form 6-K.
On Stock Titan’s SEC filings page for ORIS, users can access these documents as they are furnished to EDGAR and review AI-powered summaries that highlight key sections. These summaries can help explain complex tables, capital structure terms, and narrative disclosures in plain language, while links to the underlying filings allow for deeper analysis of Oriental Rise’s financial results, corporate actions, and ongoing reporting obligations.
Oriental Rise Holdings Limited reported much weaker interim results for the six months ended June 30, 2025. Revenue fell to about
Gross profit shrank to
Administrative expenses rose to
Oriental Rise (ORIS) priced a best-efforts public offering of 14.8 million units at US$0.4681 each, targeting gross proceeds of ~US$6.9 million. Each unit contains 1 ordinary share and 1 five-year warrant. Warrants are immediately exercisable at US$0.4681, include a cashless “zero-exercise” option that delivers 2× the shares otherwise issuable, and feature automatic repricing: to 70 % of the initial price on the 5th trading day (US$0.3276) and to 50 % on the 10th day (US$0.234); share count adjusts proportionately so the nominal aggregate exercise price stays unchanged.
Maxim Group LLC is exclusive placement agent, earning a 7 % fee plus up to US$100k expenses. Closing is expected on or about 23 Jul 2025. Securities are offered under an effective F-1 (No. 333-288292).
Use of proceeds
- 28 % – expand sales network
- 34 % – production & capacity upgrades
- 38 % – working capital
The deal supplies growth capital but materially expands potential share count, posing dilution and price-pressure risks if warrants are exercised at lower repriced levels.
Oriental Rise Holdings Limited (ORIS) filed a Form F-1 to raise capital through a best-efforts offering of up to 11,363,636 Units at an assumed US$0.88 each. Every Unit contains one Ordinary Share (or a Pre-Funded Warrant) and one five-year Common Warrant. At the assumed price, gross proceeds could reach roughly US$10 million, but there is no minimum subscription, so the final amount may be materially lower.
The warrant structure is highly dilutive. Common Warrants are immediately exercisable, include a zero-cash exercise alternative that doubles share delivery, and feature automatic strike resets to 70 % and 50 % of the initial US$0.88 on the 5th and 10th trading days post-closing. These resets proportionally boost the warrant share count, allowing issuance of up to 45,454,544 additional shares with no cash inflow if investors elect zero-price exercise. Pre-Funded Warrants carry a US$0.0001 exercise price and are offered to investors who would otherwise exceed 4.99 % (optionally 9.99 %) ownership caps.
ORIS ordinary shares already trade on Nasdaq, last quoted at US$0.9658 on 16 June 2025. The new warrants will not be listed, limiting their liquidity. Maxim Group LLC is the exclusive placement agent on a reasonable best-efforts basis; proceeds are immediately available to the company because funds are not escrowed.
As both an Emerging Growth Company and a Foreign Private Issuer, Oriental Rise will benefit from reduced reporting obligations. Proceeds are earmarked for general corporate use, but the filing cautions that effective deployment is uncertain. Investors must balance the potential capital infusion against substantial dilution risk, price volatility, and the company’s exclusive operating exposure to mainland China.
FAQ
What is the current stock price of Oriental Rise (ORIS)?
What is the market cap of Oriental Rise (ORIS)?
